
10x Genomics has initiated two international research collaborations with Charité and DRFZ in Germany, and Seoul National University in South Korea, to identify blood-based biomarkers for autoimmune diseases using their Flex Apex platform. These studies aim to analyze blood samples at single-cell resolution to better understand disease activity and predict treatment responses, potentially improving precision medicine for conditions like rheumatoid arthritis, lupus, psoriatic arthritis, and alopecia areata. The collaborations will track patients over time to link immune cell changes with clinical outcomes, aiming to develop new blood tests for monitoring and treatment planning.
10x Genomics (TXG) shares are trading at USD 55.09 on Pluang as of Nov 17, 2026 04:15 WIB, down 5.33% in one day. This price is closer to the middle of its 52-week range, which spans from a low of USD 15.45 to a high of USD 97.74, indicating moderate volatility. Despite the recent drop, all Pluang orders are buys, reflecting investor interest in the health sector stock amid its new research collaborations.